Compare Humana Inc (HUM) vs Nasdaq Inc (NDAQ) Price & Performance

Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.

The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.

Nasdaq (NDAQ) trades at $91.93, down 0.37% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $8.26 billion and net income of $1.79 billion, yielding a net margin of 21.64%. Recent news highlights growth in its Financial Technology segment, including AI enhancements to the Calypso platform and new client adoptions like HSBC.

The outlook is positive given analyst consensus with a $110.71 price target and 61% buy ratings, though near-term technical weakness and high valuation ratios pose risks. Key catalysts include continued tech adoption and cross-selling, while risks involve market volatility and execution challenges in a competitive landscape.